Galectin Therapeutics (GALT) ( (GALT) ) has released its Q2 earnings. Here is a breakdown of the information Galectin Therapeutics (GALT) presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for fibrotic disease and cancer using galectin science. In its latest earnings report for the quarter ended June 30, 2025, the company reported a net loss of $7.5 million, a decrease from the $12.4 million loss in the same period last year. Operating expenses were significantly reduced, with research and development expenses dropping to $3.3 million from $9.8 million a year ago. Despite the reduction in expenses, the company continues to operate at a loss, with no revenue generated. The company’s cash and cash equivalents stood at $13.8 million, down from $15.1 million at the end of 2024. Galectin Therapeutics has secured a new $10 million line of credit to support its operations through June 2026. Looking ahead, the company plans to raise additional capital through various strategic transactions to support its ongoing research and development efforts.